How much revenue does Eli Lilly and Company make?

Eli Lilly and Company reported $65.18 billion in revenue for fiscal year 2025, up 44.7% from $45.04 billion in fiscal year 2024. In Q2 2026 revenue was $22.97 billion.

Where does Eli Lilly and Company make most of its revenue?

United States: 67% of revenue by region in fiscal year 2025, followed by Europe (18%).

What companies are similar to Eli Lilly and Company?

Listed companies of a similar size in the same industry (blood sugar management drugs) include Novo Nordisk A/S (NVO), Oramed Pharmaceuticals Inc. (ORMP), Biomea Fusion, Inc. (BMEA), Vicapsys Life Sciences, Inc. (VICP).

Eli Lilly and Company (LLY) Stock

Executive TeamFinancialsSegmentsLayoffsShareholders

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70...

At a glance

Eli Lilly and Company reported revenue of $65.18 billion for fiscal year 2025, up 44.7% from fiscal year 2024, and net income of $20.64 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $22.97 billion, up 47.7% from a year before. United States was its largest region in fiscal year 2025, with 67% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.